{"id":683891,"date":"2022-09-12T07:23:02","date_gmt":"2022-09-12T11:23:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/"},"modified":"2022-09-12T07:23:02","modified_gmt":"2022-09-12T11:23:02","slug":"cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/","title":{"rendered":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">STAMFORD, Conn., Sept.  12, 2022  (GLOBE NEWSWIRE) &#8212; Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company\u2019s financial operations.<\/p>\n<p align=\"justify\">\u201cRyan\u2019s deep financial leadership experience will be instrumental to the execution of Cara\u2019s long-term growth strategy as we continue to maximize the KORSUVA\u2122 (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position as the leader in the treatment of chronic pruritus,\u201d said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. \u201cOn behalf of the entire Cara team, I\u2019m thrilled to welcome Ryan as our CFO.\u201d<\/p>\n<p align=\"justify\">Mr. Maynard was most recently the CFO of LetsGetChecked, a global healthcare solutions company. At LetsGetChecked, Mr. Maynard built and led the company\u2019s worldwide financial organization that experienced significant revenue growth during his tenure. Previously, Mr. Maynard served in various executive roles at Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), including 10 years as CFO. At Rigel, he was a key member of the executive team that discovered, developed, and launched TAVALISSE for the treatment of chronic immune thrombocytopenia.<\/p>\n<p align=\"justify\">\u201cCara has a significant market opportunity in chronic pruritus, a strong financial foundation and multiple value catalysts to drive growth,\u201d said Mr. Maynard. \u201cI\u2019m excited to join the team and look forward to contributing to the Company\u2019s progress toward transforming the way pruritus is treated for the millions who suffer.\u201d<\/p>\n<p align=\"justify\">Mr. Maynard currently serves on the board of directors of Iovance Biotherapeutics, Inc. (Nasdaq: IOVA). He started his career at Ernst &amp; Young, LLP. He holds a B.S. in Commerce\u2013Accounting from Santa Clara University.<\/p>\n<p align=\"justify\">\n        <strong>About Cara Therapeutics<\/strong>\n      <\/p>\n<p>Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company\u2019s novel KORSUVA\u2122 (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=79XahvcfKTVpTrB-J9orHe_RoaGPzzkbPDjZsvPiiGe2CKQfeZjfRznQfx2JQjYMw0nxArpYMR49ocoLRxUg2Iz4-Rm6Me8dNtCKg9U7bQE=\" rel=\"nofollow noopener\" target=\"_blank\">www.CaraTherapeutics.com<\/a> and follow the company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WKjL_GRTmqTMN4VqvnNN1krSlL3XW2MUVUV-Z86zJHq5A3OXmOgN4KQ9mCaqo9H6OLN5UpRYc8x3nE5rUPC1vQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GHU7Lafp-qGy8fdqkJDgJkAHjjZJEqDRsl7WnEiYMf0KC95vmyCoI4StrNBD5qR73L13Trv0HEF8CbVlNXuVtqlRknqev16NpXT-ikvDqVFNSo5bmICYjdffTsAb4q13\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z6Rj77yAHHeTZ-kj2waZp0ewyBYCWJxa7eUUmGMFprmI3Ex3EHYsDWt8Q5flspyzwpYnWHAdnQfbUWPhV8lpzMnT2gI3xpZ7sS18UjmqzOrtv63CKYbsO3b5pyWwYZRG\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>.<\/p>\n<p>\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Annie Spinetta<br \/>6 Degrees<br \/>973-768-2170<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DlCZzXjFrcV_7Vw9vl1vrYpRCS2tWyWVYH8DDofK_m8PVhIk63pOoOZKcbmvbmQz7Jb9lNd9uG06Q_gxyFfKzXAol8MTOyvPurp0ULtsDAk=\" rel=\"nofollow noopener\" target=\"_blank\">aspinetta@6degreespr.com<\/a><\/p>\n<p>\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Iris Francesconi, Ph.D.<br \/>Cara Therapeutics<br \/>203-406-3700<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sddYQ5paTjSz6qHJfv8DRnPY487mbQ_fGHZq9fDdLsWXj-Y-p-byVfzHrwgz78kzMc5qzjqjQHeQlaXoxJtlpKMYpynDKVmNL8fPU1ZT9i7BJPYGDZdBqjepTdH8pysF\" rel=\"nofollow noopener\" target=\"_blank\">investor@caratherapeutics.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NmM2YzZjN2QtZjNlNC00M2I2LTk3MjQtOTZhY2NkNzE4MzdiLTEwMTc2MTI=\/tiny\/Cara-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) &#8212; Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company\u2019s financial operations. \u201cRyan\u2019s deep financial leadership experience will be instrumental to the execution of Cara\u2019s long-term growth strategy as we continue to maximize the KORSUVA\u2122 (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position as the leader in the treatment of chronic pruritus,\u201d said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. \u201cOn behalf of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-683891","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) &#8212; Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company\u2019s financial operations. \u201cRyan\u2019s deep financial leadership experience will be instrumental to the execution of Cara\u2019s long-term growth strategy as we continue to maximize the KORSUVA\u2122 (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position as the leader in the treatment of chronic pruritus,\u201d said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. \u201cOn behalf of the &hellip; Continue reading &quot;Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-12T11:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer\",\"datePublished\":\"2022-09-12T11:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/\"},\"wordCount\":464,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/\",\"name\":\"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\",\"datePublished\":\"2022-09-12T11:23:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk","og_description":"STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) &#8212; Cara Therapeutics, Inc.\u00a0(Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company\u2019s financial operations. \u201cRyan\u2019s deep financial leadership experience will be instrumental to the execution of Cara\u2019s long-term growth strategy as we continue to maximize the KORSUVA\u2122 (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position as the leader in the treatment of chronic pruritus,\u201d said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. \u201cOn behalf of the &hellip; Continue reading \"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-12T11:23:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer","datePublished":"2022-09-12T11:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/"},"wordCount":464,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/","name":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=","datePublished":"2022-09-12T11:23:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY0MzkwNyM1MTQ1MDQzIzIwMDYwMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cara-therapeutics-appoints-ryan-maynard-as-chief-financial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/683891","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=683891"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/683891\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=683891"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=683891"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=683891"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}